NASDAQ:VYNE - VYNE Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 677.78 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.09 (-3.23%)

This chart shows the closing price for VYNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VYNE Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYNE

Analyst Price Target is $21.00
▲ +677.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for VYNE Therapeutics in the last 3 months. The average price target is $21.00, with a high forecast of $28.00 and a low forecast of $11.00. The average price target represents a 677.78% upside from the last price of $2.70.

This chart shows the closing price for VYNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in VYNE Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021HC WainwrightLower Price TargetBuy$14.00 ➝ $11.00High
12/17/2020Maxim GroupReiterated RatingPositiveHigh
10/5/2020HC WainwrightBoost Price TargetBuy$12.00 ➝ $14.00High
10/2/2020Lifesci CapitalReiterated RatingOutperformHigh
10/2/2020Northland SecuritiesReiterated RatingBuy$24.00Low
8/7/2020HC WainwrightLower Price TargetBuy$14.00 ➝ $12.00Low
8/6/2020Ci CapitalReiterated RatingBuy$28.00Low
8/4/2020Northland SecuritiesReiterated RatingBuyHigh
6/1/2020Northland SecuritiesBoost Price TargetOutperform$14.00 ➝ $24.00Low
6/1/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $14.00Low
5/21/2020Northland SecuritiesInitiated CoverageOutperform$14.00High
5/13/2020BarclaysBoost Price TargetOverweight$8.00 ➝ $12.00High
5/12/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $10.00High
4/7/2020BarclaysLower Price TargetOverweight$32.00 ➝ $8.00High
4/7/2020HC WainwrightLower Price TargetBuy$32.00 ➝ $8.00High
3/25/2020BarclaysInitiated CoverageOverweight$32.00Medium
3/11/2020Bank of AmericaInitiated CoverageBuy$32.00High
2/27/2020HC WainwrightLower Price TargetBuy$40.00 ➝ $36.00High
10/18/2019HC WainwrightInitiated CoverageBuy$44.00High
5/2/2019Cantor FitzgeraldReiterated RatingBuy$100.00Medium
2/27/2019Cantor FitzgeraldReiterated RatingBuy$100.00Low
11/7/2018Cantor FitzgeraldReiterated RatingBuy$100.00Medium
10/9/2018Jefferies Financial GroupLower Price TargetHold$28.00Low
10/8/2018Cantor FitzgeraldReiterated RatingBuy$100.00High
9/6/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$100.00Medium
7/24/2018Roth CapitalInitiated CoverageBuy$116.00High
7/24/2018KeyCorpInitiated CoverageBuyHigh
4/25/2018GuggenheimReiterated RatingBuy$44.00High
4/9/2018Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
2/20/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$176.00 ➝ $176.00High
2/20/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$192.00High
2/20/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$164.00High
2/19/2018GuggenheimInitiated CoverageBuy ➝ Buy$208.00High
(Data available from 7/25/2016 forward)
VYNE Therapeutics logo
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Read More

Today's Range

Now: $2.70
Low: $2.67
High: $2.78

50 Day Range

MA: $3.50
Low: $2.69
High: $4.11

52 Week Range

Now: $2.70
Low: $2.62
High: $13.20


281,417 shs

Average Volume

845,592 shs

Market Capitalization

$138.75 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of VYNE Therapeutics?

The following Wall Street analysts have issued reports on VYNE Therapeutics in the last year: Ci Capital, HC Wainwright, Lifesci Capital, Maxim Group, Northland Securities, and Zacks Investment Research.
View the latest analyst ratings for VYNE.

What is the current price target for VYNE Therapeutics?

3 Wall Street analysts have set twelve-month price targets for VYNE Therapeutics in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 677.8%. Ci Capital has the highest price target set, predicting VYNE will reach $28.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for VYNE Therapeutics in the next year.
View the latest price targets for VYNE.

What is the current consensus analyst rating for VYNE Therapeutics?

VYNE Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYNE will outperform the market and that investors should add to their positions of VYNE Therapeutics.
View the latest ratings for VYNE.

What other companies compete with VYNE Therapeutics?

How do I contact VYNE Therapeutics' investor relations team?

VYNE Therapeutics' physical mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company's listed phone number is 800-775-7936 and its investor relations email address is [email protected] The official website for VYNE Therapeutics is